Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status
Executive Summary
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.
You may also be interested in...
AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients
The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.